Disease Burden of Invasive Meningococcal Disease in the Netherlands between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex

Clinical Infectious Diseases

Volumn 61, Issue 8, 2015, Pages 1281-1292

  Stoof, Susanne P ^a,b   Rodenburg, Gerwin D ^b   Knol, Mirjam J ^a   Rümke, Lidewij W ^b   Bovenkerk, Sandra ^c   Berbers, Guy A M ^a   Spanjaard, Lodewijk ^c,d   Van Der Ende, Arie ^c,d   Sanders, Elisabeth A M ^a,b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Department of Medical Microbiology ^*  (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Case fatality; Clonal complex; Invasive meningococcal disease; Septic shock; Sequelae

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CLINICAL FEATURE; COMORBIDITY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SURVEILLANCE; DUTCHMAN; FATALITY; FEMALE; HOSPITAL ADMISSION; HUMAN; INFANT; INTENSIVE CARE UNIT; INVASIVE MENINGOCOCCAL DISEASE; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MENINGOCOCCOSIS; MULTILOCUS SEQUENCE TYPING; NETHERLANDS; NEWBORN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; SEROTYPE; TREATMENT DURATION; CLASSIFICATION; COST OF ILLNESS; GENETICS; HOSPITALIZATION; IMMUNOLOGY; INCIDENCE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; MIDDLE AGED; MORTALITY; NEISSERIA MENINGITIDIS; PATHOLOGY; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; TIME FACTOR; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; CHILD, PRESCHOOL; COMORBIDITY; COST OF ILLNESS; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NETHERLANDS; RETROSPECTIVE STUDIES; SEROGROUP; SHOCK, SEPTIC; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 84943246330     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ506     Document Type: Article

References (46)

1. Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine 2012; 30(suppl 2):B3-9.
2. Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013; 11:17.
3. European Centre for Disease Prevention and Control (ECDC). Vaccine Scheduler. 2014. Available at: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx. Accessed 16 January 2014.
4. Bijlsma MW, Brouwer MC, Spanjaard L, et al. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination. Clin Infect Dis 2014; 59:1216-21.
5. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-61.
6. Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-43.
7. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8:851-61.
8. de Voer RM, Mollema L, Schepp RM, et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS One 2010; 5:e12144.
9. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7.
10. Pollard AJ, Green C, Sadarangani M, Snape MD. Adolescents need a booster of serogroup Cmeningococcal vaccine to protect them andmaintain population control of the disease. Arch Dis Child 2013; 98:248-51.
11. Stoof SP, van der Klis FR, van Rooijen DM, et al. Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among dutch teenagers. PLoS One 2014; 9:e100651.
12. European Centre for Disease Prevention and Control, E. Annual epidemiological report. Reporting on 2011 surveillance data and 2012 epidemic intelligence data, in Surveillance report, E. European Centre for Disease Prevention and Control, Editor. Stockholm: European Centre for Disease Prevention and Control, (ECDC), 2013.
13. Ladhani SN, Lucidarme J, Newbold LS, et al. Invasive meningococcal capsular group Y disease, England andWales, 2007-2009. Emerg Infect Dis 2012; 18:63-70.
14. Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis 2015; 60:578-85.
15. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511-20.
16. Andrews SM, Pollard AJ. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. Lancet Infect Dis 2014; 14:426-34.
17. Pouwels KB, Hak E, van der Ende A, et al. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence. Hum Vaccin Immunother 2013; 9:1129-38.
18. Tu HA, Deeks SL, Morris SK, et al. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Vaccine 2014; 32:5436-46.
19. Nohynek H, Wichmann O, D Ancona F, VENICE National Gatekeepers. National Advisory Groups and their role in immunization policy-making processes in European countries. ClinMicrobiol Infect 2013; 19:1096-105.
20. Levy C, Taha MK, Weil Olivier C, et al. Association of meningococcal phenotypes and genotypes with clinical characteristics and mortality of meningitis in children. Pediatr Infect Dis J 2010; 29:618-23.
21. Trotter CL, Fox AJ, Ramsay ME, et al. Fatal outcome from meningococcal disease-an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin. J Med Microbiol 2002; 51:855-60.
22. Zarantonelli ML, Lancellotti M, Deghmane AE, et al. Hyperinvasive genotypes of Neisseria meningitidis in France. Clin Microbiol Infect 2008; 14:467-72.
23. Heckenberg SG, de Gans J, Brouwer MC, et al. Clinical features, outcome, and meningococcal genotype in 258 adults with meningococcal meningitis: a prospective cohort study. Medicine (Baltimore) 2008; 87:185-92.
24. Jansen AG, Rodenburg GD, de Greeff SC, et al. Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. Vaccine 2009; 27:2394-401.
25. Ouchterlony O. Antigen-antibody reactions in gels. Acta Pathol Microbiol Scand 1949; 26:507-15.
26. Maiden MC, Bygraves JA, Feil E, et al.Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998; 95:3140-5
27. Brandtzaeg P, van Deuren M. Classification and pathogenesis of meningococcal infections. Methods Mol Biol 2012; 799:21-35.
28. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003; 31:1250-6.
29. de Greeff SC, de Melker HE, Schouls LM, et al. Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003-2005. Eur J Clin Microbiol Infect Dis 2008; 27:985-92.
30. Scholten RJ, Bijlmer HA, Valkenburg HA, et al. Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol Infect 1994; 112:115-24.
31. Brouwer MC, Read RC, van de Beek D. Host genetics and outcome in meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:262-74.
32. Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J 2013; 32:e20-5.
33. Skoczynska A, Wasko I, Kuch A, et al. A decade of invasive meningococcal disease surveillance in Poland. PLoS One 2013; 8:e71943.
34. Spanjaard L, Bol P, de Marie S, et al. Association of meningococcal serogroups with the course of disease in the Netherlands, 1959-83. Bull World Health Organ 1987; 65:861-8.
35. Trotter CL, Chandra M, Cano R, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31:27-36.
36. Healy CM, Butler KM, Smith EO, et al. Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995-2000. Clin Infect Dis 2002; 34:1323-30.
37. Maat M, Buysse CM, Emonts M, et al. Improved survival of children with sepsis and purpura: effects of age, gender, and era. Crit Care 2007; 11:R112.
38. Borg J, Christie D, Coen PG, et al. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics 2009; 123:e502-9.
39. Buysse CM, Raat H, Hazelzet JA, et al. Surviving meningococcal septic shock: health consequences and quality of life in children and their parents up to 2 years after pediatric intensive care unit discharge. Crit Care Med 2008; 36:596-602.
40. Bijlsma MW, Bekker V, Brouwer MC, et al. Epidemiology of invasive meningococcal disease in the Netherlands, 1960-2012: an analysis of national surveillance data. Lancet Infect Dis 2014; 14:805-12.
41. Centers for Disease Control and Prevention (CDC). Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2013, CDC, Editor. 2013.
42. Public Health Agency of Canada. Notifiable Diseases On-Line. Available at: http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/charts.php?c=pl. Accessed 8 October 2014.
43. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2011, in Surveillance report, European Centre for Disease Prevention and Control, Editor. Stockholm: ECDC, 2013.
44. Hepkema H, Pouwels KB, van der Ende A, et al. Meningococcal serogroup A, C, W(1)(3)(5) and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLoS One 2013; 8:e65036.
45. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27(suppl 2):B51-63.
46. Brehony C, Trotter CL, Ramsay ME, et al. Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development. Clin Vaccine Immunol 2014; 21:847-53.